JPRN-UMIN000007863已完成未知
A second phase study for the cancer pain: Drug Rotation from Oral Opioid to Daily type Transdermal Fentanyl tape. - PROOF study
ISESAKI MUNICIPAL HOSPITA0 个研究点目标入组 20 人开始时间: 2012年5月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with serious hepatic, renal, heart or respiratory dysfunctions 2. Patients with medical history of psychiatry disease 3. Pregnant or nursing patients and patients who may be pregnant 4. Patients with disturbed consciousness 5. Contraindication to opioid 6. Patients who has received narcotic antagonist analgesic 7. Patients who is evaluated as in appropriate for this study by investigator
研究者
相似试验
尚未招募
Unknown
Study with cancer patients followed at the Cecon Foundation Pain Therapy and Palliative Care Service to analyze whether a Meditation intervention using Virtual Reality glasses will alleviate Pain and improve patients' quality of lifeQuality of lifeMeditationVirtual RealityPalliative MedicineF04.754.539RBR-77sqd4zFundação Centro de Controle de Oncologia do Estado do Amazonas - FCECO
招募中
不适用
Objective evaluation of cancer pain using non-contact sensorJPRN-UMIN000035330Tottori University Faculty of Medicine40
已完成
不适用
Anti-tumor efficacy of TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy Using BALF, Plasma or Pleural EffusioNeoplasmsKCT0003232Asan Medical Center63
进行中（未招募）
1 期
A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumorslocally advanced (primary or recurrent) or metastatic solid tumors with a pathogenic or likely pathogenic germline or loss-of-function somatic BRCA1, or BRCA2, or ATM gene defectMedDRA version: 20.0 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864EUCTR2018-000345-39-NLPfizer Inc., 235 East 42nd Street, New York, NY 10017541
已完成
2 期
A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant TumorsNL-OMON48840Pfizer22